XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.25.3

Investments | 9 Months Ended
--- | ---
Sep. 30, 2025
Investments, Debt and Equity Securities [Abstract] |
Investments | Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following:
| September 30, 2025
| Amortized Cost |  | Gross unrealized |  | Estimated Fair Value
(In thousands) |  | Gains |  | Losses |
Available-for-sale securities, current portion |  |  |  |  |  |  |
U.S. government securities | $ | 10,414 |  |  | $ | 19 |  |  | $ | — |  |  | $ | 10,433 |
Corporate debt securities | 33,327 |  |  | 55 |  |  | — |  |  | 33,382 |
Other debt securities | 5,648 |  |  | 10 |  |  | — |  |  | 5,658 |
Total short-term | 49,389 |  |  | 84 |  |  | — |  |  | 49,473 |
Available-for-sale securities, long-term |  |  |  |  |  |  |
U.S. government securities | 6,456 |  |  | 13 |  |  | (1) |  |  | 6,468 |
Corporate debt securities | 7,955 |  |  | 21 |  |  | — |  |  | 7,976 |
Other debt securities | 4,985 |  |  | 15 |  |  | — |  |  | 5,000 |
Total long-term | 19,396 |  |  | 49 |  |  | (1) |  |  | 19,444 |
Total marketable securities | $ | 68,785 |  |  | $ | 133 |  |  | $ | (1) |  |  | $ | 68,917 |
| December 31, 2024
| Amortized Cost |  | Gross unrealized |  | Estimated Fair Value
(In thousands) |  | Gains |  | Losses |
Available-for-sale securities, current portion |  |  |  |  |  |  |
U.S. government securities | $ | 1,493 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 1,494 |
Corporate debt securities | 5,775 |  |  | 14 |  |  | (1) |  |  | 5,788 |
Other debt securities | 1,912 |  |  | 4 |  |  | — |  |  | 1,916 |
Total short-term | 9,180 |  |  | 19 |  |  | (1) |  |  | 9,198 |
Available-for-sale securities, long-term |  |  |  |  |  |  |
Corporate debt securities | 3,210 |  |  | 4 |  |  | (2) |  |  | 3,212 |
Other debt securities | 1,412 |  |  | 5 |  |  | (1) |  |  | 1,416 |
Total long-term | 4,622 |  |  | 9 |  |  | (3) |  |  | 4,628 |
Total marketable securities | $ | 13,802 |  |  | $ | 28 |  |  | $ | (4) |  |  | $ | 13,826 |
| September 30, 2025
(In thousands) | Amortized Cost |  | Estimated Fair Value
Due in one year or less | $ | 49,389 |  |  | $ | 49,473 |
Due after one year through five years | 19,396 |  |  | 19,444 |
Total | $ | 68,785 |  |  | $ | 68,917 |
The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:
| September 30, 2025
| Less than 12 months |  | Total
(In thousands) | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses
Corporate debt securities | $ | 2,740 |  |  | $ | (1) |  |  | $ | 2,740 |  |  | $ | (1) |
U.S. government securities | 3,441 |  |  | (1) |  |  | 3,441 |  |  | (1) |
Total | $ | 6,181 |  |  | $ | (2) |  |  | $ | 6,181 |  |  | $ | (2) |
| December 31, 2024
| Less than 12 months |  | Total
(In thousands) | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses
Corporate debt securities | $ | 2,091 |  |  | $ | (3) |  |  | $ | 2,091 |  |  | $ | (3) |
Other debt securities | 1,030 |  |  | (1) |  |  | 1,030 |  |  | (1) |
Total | $ | 3,121 |  |  | $ | (4) |  |  | $ | 3,121 |  |  | $ | (4) |
As of September 30, 2025 and December 31, 2024, all available-for-sale securities investments presented above with unrealized losses have been in an unrealized loss position for less than 12 months. As of September 30, 2025, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded. Convertible promissory note On July 18, 2025, the Company invested $2.0 million cash in a convertible promissory note issued by an unrelated third party developer of induced pluripotent stem cell ("iPSC") based products for cell therapy manufacturers. The principal and accrued paid in kind ("PIK") interest on the convertible promissory note are payable at maturity on October 1, 2028. The Company also entered into a related agreement with the iPSC developer which provides, among other things, for the Company's right to a board observer seat and certain rights related to any potential future acquisition of the iPSC developer. The Company elected the FVO to account for the convertible promissory note. For further information on the valuation considerations for the convertible promissory note, see Note 4: Fair value measurement.

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration